
Key Issues in Hemophilia Treatment Part 1: Products
An overview of the issues surrounding the collection, manufacture, pricing, and marketing of factor replacement products.
Year: 2016
Language: Polish
Author(s): World Federation of Hemophilia
Format: Document
Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese
This is not an official WFH translation. This resource has been translated with permission by a WFH National Member Organization (NMO), and is shared here with their kind permission. Translating organizations are encouraged to have translations reviewed by local experts, the WFH is not responsible for the translation or for any errors or changes to content from the original English edition. Patient organizations interested in translating a WFH resource must first obtain permission from the WFH, available here.
Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than plasma products or recombinant clotting factor concentrates, carries no risk of transmission of viral infections, and is on the World Health Organization’s (WHO) Model List of Essential Medicines (EML).

An overview of the issues surrounding the collection, manufacture, pricing, and marketing of factor replacement products.